Eisai sues Teva for patent infringement

By AVI KRAWITZ
December 9, 2005 00:47
1 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Japanese pharmaceutical company Eisai Inc. has filed a lawsuit against Teva Pharmaceutical Industries for patent infringement over Teva's generic version of Aricept, used for the treatment of Alzheimer's disease. The suit was filed in response to Teva's submission to the US Food & Drug Administration of an abbreviated new drug application (ANDA) for Aricept, the main ingredient of which is donepezil hydrochloride. Eisai said in a statement Thursday that it holds a patent on the donepezil component of the drug which is valid until November 25, 2010, and that it would "vigorously enforce and defend that patent." Investors were not too concerned about the suit, however, as Teva shares continued to rise following the Jerusalem-based company's announcement Wednesday that it received final FDA approval for its ANDA to market Oxycodone Extended Release Tablets in 10 mg, 20 mg and 40 mg. sizes. The tablets are the generic equivalent of Purdue Pharma's Oxycontin tablets, for the treatment of pain when continuous analgesia is needed for an extended period of time. Teva said it would start shipping the drugs immediately, thus entering a $1.2 billion brand and generic market for the product. Teva shares rose 1.4% on Wednesday's announcement and a further 2.5% to close at NIS 204 on Thursday.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS